201 related articles for article (PubMed ID: 15000874)
1. Urocortin and cardiovascular protection.
Huang Y; Yao XQ; Lau CW; Chan YC; Tsang SY; Chan FL
Acta Pharmacol Sin; 2004 Mar; 25(3):257-65. PubMed ID: 15000874
[TBL] [Abstract][Full Text] [Related]
2. Effects of urocortin via ion mechanisms or CRF receptors?
Tao J; Li S
Biochem Biophys Res Commun; 2005 Oct; 336(3):731-6. PubMed ID: 16061206
[TBL] [Abstract][Full Text] [Related]
3. Physiological roles of urocortins, human homologues of fish urotensin I, and their receptors.
Suda T; Kageyama K; Sakihara S; Nigawara T
Peptides; 2004 Oct; 25(10):1689-701. PubMed ID: 15476936
[TBL] [Abstract][Full Text] [Related]
4. Urocortins and corticotropin releasing factor type 2 receptors in the hypothalamus and the cardiovascular system.
Hashimoto K; Nishiyama M; Tanaka Y; Noguchi T; Asaba K; Hossein PN; Nishioka T; Makino S
Peptides; 2004 Oct; 25(10):1711-21. PubMed ID: 15476938
[TBL] [Abstract][Full Text] [Related]
5. CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators.
Wiley KE; Davenport AP
Br J Pharmacol; 2004 Oct; 143(4):508-14. PubMed ID: 15381637
[TBL] [Abstract][Full Text] [Related]
6. Urocortin-induced relaxation in the human internal mammary artery.
Chen ZW; Huang Y; Yang Q; Li X; Wei W; He GW
Cardiovasc Res; 2005 Mar; 65(4):913-20. PubMed ID: 15721872
[TBL] [Abstract][Full Text] [Related]
7. Involvement of the corticotropin-releasing factor (CRF) type 2 receptor in CRF-induced thyrotropin release by the amphibian pituitary gland.
Okada R; Miller MF; Yamamoto K; De Groef B; Denver RJ; Kikuyama S
Gen Comp Endocrinol; 2007 Feb; 150(3):437-44. PubMed ID: 17188689
[TBL] [Abstract][Full Text] [Related]
8. Corticotropin releasing factor receptor 1 (CRF1) and CRF2 agonists exert an anti-inflammatory effect during the early phase of inflammation suppressing LPS-induced TNF-alpha release from macrophages via induction of COX-2 and PGE2.
Tsatsanis C; Androulidaki A; Dermitzaki E; Gravanis A; Margioris AN
J Cell Physiol; 2007 Mar; 210(3):774-83. PubMed ID: 17117478
[TBL] [Abstract][Full Text] [Related]
9. Differential monoaminergic, neuroendocrine and behavioural responses after central administration of corticotropin-releasing factor receptor type 1 and type 2 agonists.
de Groote L; Peñalva RG; Flachskamm C; Reul JM; Linthorst AC
J Neurochem; 2005 Jul; 94(1):45-56. PubMed ID: 15953348
[TBL] [Abstract][Full Text] [Related]
10. Widespread tissue distribution and diverse functions of corticotropin-releasing factor and related peptides.
Boorse GC; Denver RJ
Gen Comp Endocrinol; 2006 Mar; 146(1):9-18. PubMed ID: 16413023
[TBL] [Abstract][Full Text] [Related]
11. [Urocortin: molecular biology and cardiovascular effects].
Raddino R; Pedrinazzi C; Zanini G; Robba D; Bonadei I; Scarabelli TM; Cas LD
G Ital Cardiol (Rome); 2007 Apr; 8(4):236-45. PubMed ID: 17506295
[TBL] [Abstract][Full Text] [Related]
12. The effects of CRF and the urocortins on [3H]GABA release from the rat amygdala--an in vitro superfusion study.
Bagosi Z; Jászberényi M; Szabó G; Telegdy G
Brain Res Bull; 2008 Jan; 75(1):15-7. PubMed ID: 18158090
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the relaxant action of urocortin, a new peptide related to corticotropin-releasing factor in the rat isolated basilar artery.
Schilling L; Kanzler C; Schmiedek P; Ehrenreich H
Br J Pharmacol; 1998 Nov; 125(6):1164-71. PubMed ID: 9863643
[TBL] [Abstract][Full Text] [Related]
14. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.
Hoare SR; Sullivan SK; Fan J; Khongsaly K; Grigoriadis DE
Peptides; 2005 Mar; 26(3):457-70. PubMed ID: 15652653
[TBL] [Abstract][Full Text] [Related]
15. Localization and physiological roles of urocortin.
Oki Y; Sasano H
Peptides; 2004 Oct; 25(10):1745-9. PubMed ID: 15476941
[TBL] [Abstract][Full Text] [Related]
16. Human urocortin 2, a corticotropin-releasing factor (CRF)2 agonist, and ovine CRF, a CRF1 agonist, differentially alter feeding and motor activity.
Zorrilla EP; Reinhardt LE; Valdez GR; Inoue K; Rivier JE; Vale WW; Koob GF
J Pharmacol Exp Ther; 2004 Sep; 310(3):1027-34. PubMed ID: 15115804
[TBL] [Abstract][Full Text] [Related]
17. Evidence supporting a role for corticotropin-releasing factor type 2 (CRF2) receptors in the regulation of subpopulations of serotonergic neurons.
Staub DR; Evans AK; Lowry CA
Brain Res; 2006 Jan; 1070(1):77-89. PubMed ID: 16403469
[TBL] [Abstract][Full Text] [Related]
18. Corticotropin-releasing factor, urocortin 1, and their receptors in the mouse spinal cord.
Korosi A; Kozicz T; Richter J; Veening JG; Olivier B; Roubos EW
J Comp Neurol; 2007 Jun; 502(6):973-89. PubMed ID: 17444496
[TBL] [Abstract][Full Text] [Related]
19. Urocortins and the regulation of gastrointestinal motor function and visceral pain.
Martinez V; Wang L; Million M; Rivier J; Taché Y
Peptides; 2004 Oct; 25(10):1733-44. PubMed ID: 15476940
[TBL] [Abstract][Full Text] [Related]
20. Modulation of Ca2+ influx by corticotropin-releasing factor (CRF) family of peptides via CRF receptors in rat pancreatic beta-cells.
Kageyama K; Kimura R; Suga S; Ogawa Y; Suda T; Wakui M
Peptides; 2006 Jul; 27(7):1814-9. PubMed ID: 16513211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
